Stockreport

Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End

Chimerix, Inc.  (CMRX) 
Last chimerix, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.chimerix.com/investor-relations
PDF Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Compa [Read more]